The $32,000 Infusion Illusion
The new Alzheimer’s drugs promise to slow down cognitive decline, but the hidden logistics might break your calendar before they help your parent.
Let’s talk about Leqembi. The FDA approved this drug with headline-grabbing promises of slowing down cognitive decline by about 27 percent over 18 months. What the press releases skipped was the calendar math. To get that 27 percent, your 79-year-old parent has to sit in an infusion chair every two weeks, indefinitely, while you spend your Tuesdays playing amateur ambulance driver and insurance referee.
The direct answer
The new Alzheimer’s infusion drugs—specifically Leqembi and Kisunla—are not pills you pick up at the drive-thru. They require bi-weekly or monthly intravenous infusions, frequent and expensive brain MRIs to monitor for internal bleeding, and a mountain of prior authorization paperwork. If you do not have a dedicated family member who can treat care coordination as a part-time job, these drugs are functionally inaccessible.
The Invisible Calendar Tax
The sticker price of Leqembi is $26,500 per year, while Kisunla lands around $32,000. But the currency you will actually run out of first is time. Every two weeks, someone has to drive your parent to a specialized infusion center, wait three hours for the drip and the safety observation window, and drive them home.
That is 26 half-days a year, assuming no traffic, no delays, and no scheduling conflicts. If you work a standard job, that is 104 hours of paid time off gone just for the transit and administration. If your parent lives in a rural area or a mid-sized suburb, that infusion center might be an hour's drive away, doubling your commitment.
And this is not a short-term sprint. This is a permanent lifestyle change until the drug stops working or the side effects force you to halt. If you cannot personally drive them, hiring private transport can easily add $150 per trip, ballooning your out-of-pocket expenses by nearly $4,000 annually.
The MRI Gauntlet and ARIA
You cannot simply get the infusion and go home to forget about it. These drugs work by clearing amyloid plaques from the brain, which can cause a side effect called ARIA, or Amyloid-Related Imaging Abnormalities. In plain English, this means localized brain swelling or microscopic bleeding.
To catch ARIA before it becomes life-threatening, the FDA mandates regular MRI scans. For Leqembi, your parent needs brain scans before the fifth, seventh, and fourteenth infusions. That means three extra appointments, three more co-pays, and three more rounds of arguing with insurance companies who love to deny coverage for preventative imaging.
If the MRI shows brain swelling, the infusions stop immediately, throwing your entire schedule and emotional state into a tailspin. You are suddenly caught in a loop of specialist consults, repeat scans, and anxious waiting, all while watching the clock tick on your parent's cognitive window.
The Insurance Paperwork Black Hole
Medicare does cover these drugs, but only if your provider participates in a registry to track real-world outcomes. This sounds like simple bureaucracy, but it translates to a massive administrative hurdle for local clinics. Many smaller practices simply refuse to prescribe the drugs because they do not have the staff to handle the paperwork.
If you do find a prescribing doctor, your parent's specific diagnosis must fit into a razor-thin diagnostic window: mild cognitive impairment or mild dementia. If their decline has progressed even slightly past "mild," insurance will deny the claim, leaving you with a $2,200 bill per vial.
This creates a cruel paradox. By the time many families notice the symptoms, get an appointment with a specialist (which often takes six months), and secure insurance approval, the window of eligibility has already closed.
Common mistakes
- Assuming "covered by Medicare" means free.
Medicare Part B typically covers 80% of outpatient drugs, leaving you with a 20% co-insurance rate that amounts to over $5,000 annually out of pocket, not including the cost of MRIs, specialist visits, and facility fees. Unless your parent has a robust Medigap policy, you will face massive surprise bills. - Waiting too long to start the diagnostic process.
These drugs only work—and are only approved—for the earliest stages of cognitive decline. If you wait until your parent is wandering or unable to manage their daily finances, they will be disqualified immediately. Start the cognitive testing now, even if they insist they are just having normal aging moments.
Frequently asked
How much does Leqembi actually cost out of pocket with Medicare?
While Medicare covers the drug, people are generally responsible for a 20% co-insurance payment under Part B. This translates to roughly $5,300 per year just for the drug itself. When you add the required MRIs, specialist co-pays, and infusion center facility fees, the annual out-of-pocket cost easily climbs past $8,000 for families without supplemental insurance.
What is the difference between Leqembi and Kisunla?
Leqembi requires infusions every two weeks and targets early amyloid plaques. Kisunla is administered once a month and has a unique stopping point: once brain scans show the plaques are gone, individuals can stop taking it. While Kisunla's monthly schedule is easier to manage, its annual list price of $32,000 is higher than Leqembi's $26,500, and the monthly dose is larger, which can influence side effect profiles.
Can my parent get these infusions at home?
Currently, no. Because of the risk of severe allergic reactions during administration and the need for immediate access to emergency equipment, these infusions must be done at certified outpatient centers or hospital clinics. This means you cannot bypass the transit and scheduling hurdles by hiring a home nurse.
Sources
More from Inside the Industry → · Back to Perch · Browse all stories